Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18–65 years: NILG ALL 10/07Renato Bassan, Alessandro Rambaldi, Anna Maria Scattolin et al.|Blood Cancer Journal|2020Cited by 45
Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AMLRenato Bassan, Alessandro Rambaldi, Tamara Intermesoli et al.|Blood Advances|2019Cited by 33
Final Results of Northern Italy Leukemia Group (NILG) Trial 10/07 Combining Pediatric-Type Therapy with Minimal Residual Disease Study and Risk-Oriented Hematopoietic Cell Transplantation in Adult Acute Lymphoblastic Leukemia (ALL)Renato Bassan, Alessandro Rambaldi, Arianna Masciulli et al.|Blood|2016Cited by 22
Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06Chiara Caprioli, Alessandro Rambaldi, Federico Lussana et al.|Haematologica|2020Cited by 22
Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trialGiacomo Gianfaldoni, Renato Bassan, Francesco Mannelli et al.|Blood Advances|2020Cited by 15